These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7230 related articles for article (PubMed ID: 2144741)

  • 21. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
    Huang A; Fan H; Taylor WR; Wright JA
    Cancer Res; 1997 Nov; 57(21):4876-81. PubMed ID: 9354452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 23. Chromosome rearrangements associated with CAD gene amplification. Experiments with cell hybrids.
    Viaggi S; Nüsse M; Ottaggio L; Bonatti S
    Mutat Res; 1992 Jan; 265(1):9-21. PubMed ID: 1370246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts.
    Kinsella AR; Haran MS
    Cancer Res; 1991 Apr; 51(7):1855-9. PubMed ID: 2004369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The enhancement of the frequency of resistance to N-phosphonoacetyl-L-aspartate and methotrexate by 1-beta-D-arabinofuranosylcytosine: the effect of dipyridamole.
    Goz B; Jeffs L
    J Pharmacol Exp Ther; 1994 Aug; 270(2):480-4. PubMed ID: 8071840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification.
    Huang A; Wright JA
    Oncogene; 1994 Feb; 9(2):491-9. PubMed ID: 7904743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 12-O-tetradecanoylphorbol-13-acetate on selection of drug-resistant phenotypes in rodent cells.
    Bojan F; Kinsella AR; Fox M
    IARC Sci Publ; 1984; (56):265-73. PubMed ID: 6536598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts.
    Schaefer DI; Livanos EM; White AE; Tlsty TD
    Cancer Res; 1993 Oct; 53(20):4946-51. PubMed ID: 8402685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The presence of amplified regions affects the stability of chromosomes in drug-resistant Chinese hamster cells.
    Miele M; Bonatti S; Menichini P; Ottaggio L; Abbondandolo A
    Mutat Res; 1989 May; 219(3):171-8. PubMed ID: 2567961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 32. Increased gene amplification in immortal rodent cells deficient for the DNA-dependent protein kinase catalytic subunit.
    Mondello C; Rebuzzini P; Dolzan M; Edmonson S; Taccioli GE; Giulotto E
    Cancer Res; 2001 Jun; 61(11):4520-5. PubMed ID: 11389084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 35. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene amplification in fibroblasts from ataxia telangiectasia (AT) patients and in X-ray hypersensitive AT-like Chinese hamster mutants.
    Mondello C; Faravelli M; Pipitone L; Rollier A; Di Leonardo A; Giulotto E
    Carcinogenesis; 2001 Jan; 22(1):141-5. PubMed ID: 11159752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical modulation of 5-fluorouracil by PALA: mechanism of action.
    Martin DS
    Adv Exp Med Biol; 1993; 339():153-63; discussion 165-7. PubMed ID: 8178714
    [No Abstract]   [Full Text] [Related]  

  • 38. Selection of N-(phosphonacetyl)-L-aspartate resistant Chinese hamster mutants in the presence of the uridine uptake inhibitor dipyridamole.
    Tessera L; Mucciolo E; Bertoni L; Giulotto E
    Anticancer Res; 1995; 15(1):189-92. PubMed ID: 7733632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of the activity of PALA by dipyridamole.
    Chan TC; Young B; King ME; Taetle R; Howell SB
    Cancer Treat Rep; 1985 Apr; 69(4):425-30. PubMed ID: 3857969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence that resistance to osmotic stress is mediated by gene amplification.
    Harris M
    Somat Cell Mol Genet; 1997 Jan; 23(1):19-25. PubMed ID: 9217998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 362.